» Articles » PMID: 37915591

MUC1-C Integrates Aerobic Glycolysis with Suppression of Oxidative Phosphorylation in Triple-negative Breast Cancer Stem Cells

Abstract

Activation of the MUC1-C protein promotes lineage plasticity, epigenetic reprogramming, and the cancer stem cell (CSC) state. The present studies performed on enriched populations of triple-negative breast cancer (TNBC) CSCs demonstrate that MUC1-C is essential for integrating activation of glycolytic pathway genes with self-renewal and tumorigenicity. MUC1-C further integrates the glycolytic pathway with suppression of mitochondrial DNA (mtDNA) genes encoding components of mitochondrial Complexes I-V. The repression of mtDNA genes is explained by MUC1-C-mediated (i) downregulation of the mitochondrial transcription factor A (TFAM) required for mtDNA transcription and (ii) induction of the mitochondrial transcription termination factor 3 (mTERF3). In support of pathogenesis that suppresses mitochondrial ROS production, targeting MUC1-C increases (i) mtDNA gene transcription, (ii) superoxide levels, and (iii) loss of self-renewal capacity. These findings and scRNA-seq analysis of CSC subpopulations indicate that MUC1-C regulates self-renewal and redox balance by integrating activation of glycolysis with suppression of oxidative phosphorylation.

Citing Articles

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.

Serrano Garcia L, Javega B, Llombart Cussac A, Gion M, Perez-Garcia J, Cortes J Front Immunol. 2024; 15:1513421.

PMID: 39735530 PMC: 11671371. DOI: 10.3389/fimmu.2024.1513421.


FDFT1 maintains glioblastoma stem cells through activation of the Akt pathway.

Mo H, Shao J, Li Z, Zeng P, Yin X, Huang Y Stem Cell Res Ther. 2024; 15(1):492.

PMID: 39707501 PMC: 11662426. DOI: 10.1186/s13287-024-04102-7.


Oxidative Phosphorylation as a Predictive Biomarker of Oxaliplatin Response in Colorectal Cancer.

Martinez-Bernabe T, Pons D, Oliver J, Sastre-Serra J Biomolecules. 2024; 14(11).

PMID: 39595536 PMC: 11591675. DOI: 10.3390/biom14111359.


MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression.

Bhattacharya A, Wang K, Penailillo J, Chan C, Fushimi A, Yamashita N Oncogene. 2024; 43(28):2199-2214.

PMID: 38802648 PMC: 11226401. DOI: 10.1038/s41388-024-03068-3.

References
1.
Bianchini G, De Angelis C, Licata L, Gianni L . Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2021; 19(2):91-113. DOI: 10.1038/s41571-021-00565-2. View

2.
Grasso D, Zampieri L, Capeloa T, Van de Velde J, Sonveaux P . Mitochondria in cancer. Cell Stress. 2020; 4(6):114-146. PMC: 7278520. DOI: 10.15698/cst2020.06.221. View

3.
Kosugi M, Ahmad R, Alam M, Uchida Y, Kufe D . MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS One. 2011; 6(11):e28234. PMC: 3225393. DOI: 10.1371/journal.pone.0028234. View

4.
Bhattacharya A, Fushimi A, Yamashita N, Hagiwara M, Morimoto Y, Rajabi H . MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells. Mol Cancer Res. 2022; 20(4):556-567. PMC: 8983489. DOI: 10.1158/1541-7786.MCR-21-0672. View

5.
Nandi A, Chakrabarti R . Assessment of Breast Cancer Stem Cell Activity Using a Spheroid Formation Assay. Methods Mol Biol. 2022; 2429:485-500. DOI: 10.1007/978-1-0716-1979-7_33. View